Harvest Investment Services completely exited its position in Adaptive Biotechnologies, selling 356,114 shares worth approximately $5.67 million during Q1 2026. The sale was part of a broader portfolio restructuring where the firm closed 48 positions. Despite the exit, ADPT shares have appreciated 57.78% over the prior year, with strong Q1 growth in cancer diagnostic testing.

Adaptive Biotechnologies' COO Julie Rubinstein sold 19,037 shares worth approximately $271,000 on April 27, 2026, as part of a pre-established Rule 10b5-1 trading plan. The sale represented only 4.8% of her holdings, and she maintains significant equity stakes with 377,802 directly-held shares and 45,731 options. The transaction is not considered a red flag, as the company reported strong 55% revenue growth in 2025 while significantly reducing operating losses.

Adaptive Biotechnologies' President and COO Julie Rubinstein sold 57,180 shares (~$826,000) between April 14-16, 2026, through the exercise and immediate sale of stock options. The analyst characterizes this as a liquidity event rather than a loss of confidence, noting Rubinstein retains 408,160 shares and 148,770 options. The company's MRD cancer monitoring revenue grew 46% last year, with expanded Medicare coverage supporting future growth.

Adaptive Biotechnologies' President and COO Julie Rubinstein sold 38,120 shares worth approximately $554,000 through a pre-arranged trading plan. Despite the insider sale, the company reported strong fundamentals with 55% year-over-year revenue growth to $277 million, driven by its MRD segment which now represents over 75% of sales. Net losses narrowed significantly from $159.6 million to $59.5 million, and the MRD segment achieved positive adjusted EBITDA. The article emphasizes that the sale appears compensation-driven rather than a bearish signal, with the real focus being on whether the company can sustain profitability growth.

Adaptive Biotechnologies' President and COO Julie Rubinstein sold 81,342 shares (~$1.21 million) in a pre-scheduled transaction under a 10b5-1 plan, reducing her direct holdings by 11.22%. However, she retains 643,471 shares and over 510,000 vested options. The sale occurred as the stock has gained 51% over the past year. The company's core MRD (Minimal Residual Disease) business achieved 46% revenue growth in 2025 and profitability, with guidance for positive adjusted EBITDA and free cash flow by year-end 2026.

Julie Rubinstein, president and COO of Adaptive Biotechnologies, sold 179,703 shares for approximately $2.37 million in March 2026 through a pre-arranged Rule 10b5-1 trading plan tied to tax withholding obligations from RSU vesting. The sale reduced her direct holdings by 26.1%, though she retains substantial stock options. The transaction should not be viewed as a bearish signal, as the company has demonstrated strong momentum with 55% year-over-year revenue growth in 2025, reaching $277 million, and achieving positive adjusted EBITDA and cash flow.

Bank of America expects Pfizer's 2026 financial outlook to remain flat, with challenges from ongoing patent exclusivity losses and limited pipeline catalysts. The company is focusing on areas like obesity treatments, antibody-drug conjugates, and pneumococcal franchise development.

Adaptive Biotechnologies presented 90 abstracts at the ASH Annual Meeting, highlighting its clonoSEQ® test's effectiveness in guiding treatment interventions across multiple blood cancer types, demonstrating precision in measurable residual disease (MRD) monitoring.

Adaptive Biotechnologies' stock dropped after Natera acquired Foresight Diagnostics for $275 million upfront, raising competitive concerns in the blood-cancer minimal residual disease (MRD) market.

Adaptive Biotechnologies reported strong Q2 2025 results with 36% revenue growth, primarily driven by minimal residual disease (MRD) business. The company beat analyst expectations and raised its MRD revenue guidance for 2025.

The U.S. minimal residual disease testing market is projected to reach $2020 million by 2033, growing at a 9.38% CAGR, driven by rising cancer rates and advancements in precision medicine technologies like NGS and flow cytometry.

Adaptive Biotechnologies presented new data on the use of its clonoSEQ test for measurable residual disease (MRD) assessment in various blood cancer types at major medical conferences.